iiinova — where your digital self keeps evolving

Lung Cancer Europe @lungcancereurope.bsky.social · 20h

🆕 research looks at what may happen before some smoking-related lung cancers develop. Long-term cigarette smoke exposure changed lung stem cells in a lab model, with KRAS linked to adenocarcinoma and TP53 loss to squamous cell carcinoma. #LCSM #lungcancer www.hopkinsmedicine.org/news/newsroo...

031

Lung Cancer Europe @lungcancereurope.bsky.social · 06/10/2026

#Lungcancer screening is also a chance to offer help with 🚭 . A US trial of 3.2K people referred for screening, 8.8% offered medication & financial incentives had verified abstinence at 6 mths, Vs 4.3% given usual support. Practical help, without judgement. jamanetwork.com/journals/jam... #LCSM

051

Lung Cancer Europe @lungcancereurope.bsky.social · 06/10/2026

It’s the FINAL week for our 12th Annual Report Survey. We’re gathering evidence on quality of life and support needs for people affected by #lungcancer across Europe. Please take part if eligible, or share with patients, members and networks: es.surveymonkey.com/r/LungCancer... #LCSM

040

Lung Cancer Europe @lungcancereurope.bsky.social · 05/10/2026

A clear first scan doesn’t end the need for #lungcancer screening. In BioMILD, 105 of 3,464 people who smoked heavily had a negative CT but were later diagnosed with lung cancer. Median follow-up: 9.4 years. Screening needs follow-up. #LCSM www.lungcancerjournal.info/article/S016...

040

Lung Cancer Europe @lungcancereurope.bsky.social · 04/10/2026

A rare inherited EGFR variant has been linked to around 25× higher odds of #LungCancer. - genetic data from 3.3M+ - could inform future genetic testing & screening How do we make sure evidence like this leads to earlier detection & fair access to screening? hms.harvard.edu/news/rare-in... #LCSM

071

Lung Cancer Europe @lungcancereurope.bsky.social · 04/10/2026

In an I3LUNG study of 2,396 people with advanced #lungcancer, an AI model using routine data predicted 24-month survival better than PD-L1 alone. Performance fell at another centre, so it needs more testing. New research in Nature Medicine: www.nature.com/articles/s41... #LCSM

040

Lung Cancer Europe @lungcancereurope.bsky.social · 03/10/2026

The EU Biotech Act is moving through the European Parliament. For #lungcancer, key issues include biomarker testing, cross-border trials, patient involvement and access to innovation across Europe. lungcancereurope.eu/news/the-eu-... #LCSM

051

Lung Cancer Europe @lungcancereurope.bsky.social · 29/09/2026

The link between #lungcancer and heart health runs both ways. The conditions share risks, and some lung cancer treatments can affect the heart. More on the evidence and what it means for care this #WorldHeartDay: lungcancereurope.eu/news/lung-ca... #LCSM

051

Lung Cancer Europe @lungcancereurope.bsky.social · 25/09/2026

People with #LungCancer should not have to coordinate every part of their care themselves. Today at #WCC2026, our VP presented collab work with LCPN on patient navigation: practical support to help people move between services and get the care they need. lungcancereurope.eu/news/what-is... #LCSM

061

Lung Cancer Europe @lungcancereurope.bsky.social · 25/09/2026

In a small trial in Turkey, 84 people newly diagnosed with non-small cell #LungCancer were assigned to a 12-wk nurse navigation programme or usual care. The navigation group reported less depression & stress, & better QOL + fewer emergency department visits. #LCSM pubmed.ncbi.nlm.nih.gov/42686455/

071

Lung Cancer Europe @lungcancereurope.bsky.social · 24/09/2026

What helps patient advisers take part in research decisions? Join us and the European Patients’ Forum on 12 November for an IDERHA webinar. We’ll share lessons from its Patient Advisory Board and hear your experiences. 14:00–15:30 CET. Register: www.iderha.org/news/iderha-...

050

Lung Cancer Europe @lungcancereurope.bsky.social · 23/09/2026

#LungCancer surgery became more common in England. Among 308,000+ people with NSCLC, the proportion having surgery rose from 15.4% (2015) to 20.9% (2023). Stage I diagnoses rose from 17.4% to 26.8%. Early diagnosis must lead to timely treatment. bmjopen.bmj.com/content/16/9... #LCSM

051

Lung Cancer Europe @lungcancereurope.bsky.social · 22/09/2026

Earlier #lungcancer testing found no target. Broader genomic profiling found a driver alteration in 37%. 🆕 Japanese study inclu 2,296 people with advanced or recurrent #NSCLC. For Europe we need the right test, early enough, followed by trtmt that matches the result. doi.org/10.1016/j.lu... #LCSM

050

Lung Cancer Europe @lungcancereurope.bsky.social · 21/09/2026

Could MRI find #lungcancer spread that CT misses? A 🆕 collagen-targeted contrast agent detected lung tumours as small as 0.6 mm & adrenal metastases as small as 0.1 mm in preclinical models of LKB1-mutant lung adenocarcinoma. Could it do the same in people? doi.org/10.1126/scia... #LCSM

061

Lung Cancer Europe @lungcancereurope.bsky.social · 20/09/2026

What can have the biggest impact on quality of life after a #lungcancer diagnosis? Fatigue, breathlessness, work, finances & loss of independence are just some of the issues people may face. Please help us reach people living with lung cancer & caregivers: es.surveymonkey.com/r/LungCancer... #LCSM

040

Lung Cancer Europe @lungcancereurope.bsky.social · 17/09/2026

This week, Germany announced a new network to help deliver #lungcancer screening in practice. The network links 25 radiology screening sites with specialist second-reading centres in Heidelberg, supporting consistent reporting and follow-up. Screening is about delivery as well as policy. #LCSM

052

Lung Cancer Europe @lungcancereurope.bsky.social · 15/09/2026

The science has moved. Now Europe must. #WCLC26 brought advances that could change #lungcancer care. The next job is turning evidence into approval, implementation and equitable access across Europe. Our week in Seoul: lungcancereurope.eu/news/lung-ca...

040

Lung Cancer Europe @lungcancereurope.bsky.social · 13/09/2026

Better #lungcancer diagnosis needs collaboration across the whole pathway. At #WCLC26, our VP presented collaborative work with Lung Cancer Policy Network work drawing on evidence, 12 expert interviews and contributions from multidisciplinary members. #LCSM lungcancereurope.eu/news/lung-ca...

04711

Lung Cancer Europe @lungcancereurope.bsky.social · 13/09/2026

🧠 Phase 3 MAVERICK results at #WCLC26 could change care for small cell #lungcancer. MRI surveillance alone protected cognitive outcomes vs adding preventive brain radiotherapy, with no significant diff in survival so far. If confirmed, this could spare some people with #SCLC unnecessary treatment.

051

Lung Cancer Europe @lungcancereurope.bsky.social · 12/09/2026

Our President joined speakers from across the lung cancer community at #WCLC2026 today for From Evidence to Action: Practical Skills for Engaging Policymakers on Earlier #LungCancer Detection. She spoke about handling objections to screening & how advocates can respond when concerns are raised.

051

Lung Cancer Europe @lungcancereurope.bsky.social · 10/09/2026

Missed our #SCLC webinar, or want to revisit the discussion? Watch the replay of Fast diagnosis, fragmented support: living with small-cell #lungcancer in Europe. We’ve also added answers to audience Qs, including those we couldn’t cover live. lungcancereurope.eu/news/fast-di... #LCSM

040

Lung Cancer Europe @lungcancereurope.bsky.social · 09/09/2026

Thank you @europeanrespsoc.bsky.social for an excellent #ERSCongress2026 in Barcelona. We presented 2 abstracts, contributed to discussions on #lungcancer & made new connections across respiratory health. Read our round-up: lungcancereurope.eu/news/lung-ca... Now on to #WCLC26 in Seoul ✈️ #LCSM

070

Lung Cancer Europe @lungcancereurope.bsky.social · 08/09/2026

From today’s #ERSCongress2026 poster session: SCLC survey. ❌ 19/37 were offered no support 🩺 24/37 reported doctor-led decisions 🧪 1/37 reported clinical trial discussions People with #LungCancer must be part of the conversation. lungcancereurope.eu/news/lung-ca...

040

Lung Cancer Europe @lungcancereurope.bsky.social · 06/09/2026

New microplastics research presented at #ERSCongress today studied 100 people undergoing tests for lung symptoms. Microplastics were found in lung-wash samples from 66% of those diagnosed with #LungCancer, compared with 46% of those without it. lungcancereurope.eu/news/news/mi... #LCSM

092

Lung Cancer Europe @lungcancereurope.bsky.social · 06/09/2026

At #ERSCongress2026 today? Come and meet us from 12:00–13:00 at the @europeanlung.bsky.social stand in the World Village and talk to us about #LungCancer in Europe. #LCSM

040

Reposted by Lung Cancer Europe

European Lung Foundation @europeanlung.bsky.social · 06/09/2026

📍 Today's ELF picks at #ERSCongress2026 🤝 Meet patient organisations including @lungcancereurope.bsky.social in the World Village 🫁 Healthy Lungs for Life event at Plaça de la Universitat (10:00–18:30) ☕ ELF social hour (15:00–16:00) 🎤 Hear from patient representatives throughout the programme

052

Lung Cancer Europe @lungcancereurope.bsky.social · 05/09/2026

People affected by #lungcancer do not share their experiences with us so they can sit in a report. At #ERSCongress, we’re taking what they told us into wider discussions and presenting two abstracts on Tuesday: one on SCLC and one on storytelling in lung cancer awareness. #LCSM

040

Lung Cancer Europe @lungcancereurope.bsky.social · 04/09/2026

Are clinical trials holding back progress in cancer? New US opinion piece argues that cost, delays & bureaucracy are stopping promising treatments from being tested. Trial access is also a major issue for people with #LungCancer in Europe - particularly SCLC where timing is critical. #LCSM

040

Lung Cancer Europe @lungcancereurope.bsky.social · 03/09/2026

A lot of attention on daraxonrasib in RAS-mutant non-small cell #lungcancer. The phase 1/2 study reported tumour responses in more than 30%, but 54% had grade 3 or higher adverse events. Both figures need attention as it moves into phase 3. www.nejm.org/doi/full/10.... #NSCLC #LCSM

040

Lung Cancer Europe @lungcancereurope.bsky.social · 03/09/2026

200+ people have registered for today’s #SCLC webinar. There’s still time to join us. We’ll hear from people living with SCLC and others affected by it, alongside clinicians, about diagnosis, treatment and support. 15:00 CEST / 14:00 BST lungcancereurope.eu/sclc-webinar... #LungCancer #LCSM

040

Lung Cancer Europe @lungcancereurope.bsky.social · 02/09/2026

Changes after immunotherapy starts may tell more than a sample taken before it. New Cancer Cell research across 10 cancers, including non-small cell lung cancer, found that changes in the tumour immune environment better predicted response. www.sciencedirect.com/science/arti... #LungCancer #LCSM

050

Lung Cancer Europe @lungcancereurope.bsky.social · 01/09/2026

As advocates, we want to understand new approaches that could improve #lungcancer care. Co-authored by @DrewMoghanaki, this review explores MR-guided adaptive radiotherapy for tumours in difficult locations and what we still need to learn. www.mdpi.com/2072-6694/18... #LCSM

051

Lung Cancer Europe @lungcancereurope.bsky.social · 01/09/2026

Our 12th Annual Report Survey is now open. This year the focus is on quality of life and support needs. If you live in Europe and have #lungcancer, or care for someone who does, please take part 👉 es.surveymonkey.com/r/LungCancer... The more people who respond, the stronger the evidence. #LCSM

030

Lung Cancer Europe @lungcancereurope.bsky.social · 30/08/2026

🆕 research in CHEST links stronger health systems with better lung cancer outcomes. Higher health spending, stronger universal coverage, greater nursing capacity and more radiotherapy centres were associated with lower mortality relative to incidence. #LCSM doi.org/10.1016/j.ch...

061

Lung Cancer Europe @lungcancereurope.bsky.social · 29/08/2026

Interesting new #SCLC research. Researchers have found that targeting XPO1 may help make small cell #lungcancer more responsive to anti-PD-1 immunotherapy. Still preclinical, & early research, but it gives researchers another possible route to explore in SCLC. www.nature.com/articles/s41... #LCSM

040

Lung Cancer Europe @lungcancereurope.bsky.social · 27/08/2026

Could some lung neuroendocrine tumours be in the wrong box? 🆕 study of 319 lung NETs found 4 distinct molecular groups, inclu a more aggressive supra-carcinoid group with biological links to small cell #lungcancer Could help refine classification & future research link.springer.com/article/10.1...

071

Lung Cancer Europe @lungcancereurope.bsky.social · 26/08/2026

Radiotherapy is a key part of #lungcancer treatment. Could the thymus be another organ doctors should try to protect? New Annals of Oncology research in 1,107 people with NSCLC linked higher incidental thymic radiation with more distant metastases and worse survival. doi.org/10.1016/j.an... #LCSM

051

Lung Cancer Europe @lungcancereurope.bsky.social · 25/08/2026

One week to go. Our Annual Reports have built more than a decade of evidence from people affected by #lungcancer across Europe. The survey for our 12th Report opens 1 September, focusing on quality of life and support needs. The more people who take part, the stronger the evidence. #LCSM

051

Lung Cancer Europe @lungcancereurope.bsky.social · 23/08/2026

⚠️ Small cell #lungcancer has been overlooked for years. That’s starting to change. Our free webinar on 3 September is filling fast, and places are capped. Three leading clinicians on what’s moving in SCLC, and what still isn’t reaching people. Don’t leave it too late 👇 shorturl.at/68jb6 #LCSM

040

Lung Cancer Europe @lungcancereurope.bsky.social · 21/08/2026

A large analysis of 14,246 people with #LungCancer (NSCLC) found younger adults were more likely to have targetable genetic changes, including EGFR, ALK & ROS1. Nearly 58% had actionable alterations, compared with around 45% of people aged 55+. Read more: lungcancereurope.eu/news/younger... #LCSM

051

Lung Cancer Europe @lungcancereurope.bsky.social · 20/08/2026

A personalised mRNA cancer vaccine has reported positive Phase 3 results in melanoma. The same approach is already being tested in Phase 3 NSCLC trials, which is why #lungcancer specialists are paying a lot of attention. lungcancereurope.eu/personalised... #LCSM

061

Lung Cancer Europe @lungcancereurope.bsky.social · 19/08/2026

A decade of evidence on the challenges of living with #lungcancer in Europe. All 11 Lung Cancer Europe Annual Reports now available together in a dedicated portfolio on our website. Covering diagnosis, treatment, clinical trials, QOL, mental health & more. lungcancereurope.eu/annual-reports #LCSM

071

Lung Cancer Europe @lungcancereurope.bsky.social · 16/08/2026

New small cell #lungcancer data: tarlatamab had already shown a survival benefit. Now DeLLphi-304 patient-reported results show better symptom outcomes, later worsening of breathlessness, cough & chest pain, & less bother from side effects. 3 Sept webinar lungcancereurope.eu/sclc-webinar-2026 #LCSM

051

Lung Cancer Europe @lungcancereurope.bsky.social · 14/08/2026

SCLC has been overlooked & underserved for years. That’s changing fast. Be part of our free webinar on 3 Sept. 3 leading clinicians on what’s moving in small cell #lungcancer, & what still isn’t reaching people, alongside someone living with the disease sharing their experience. shorturl.at/1wAXQ

shorturl.at

Fast Diagnosis, Fragmented Support: Small Cell Lung Cancer Webinar | Lung Cancer Europe — Lung Cancer Europe | Advocacy and Access for Lung Cancer in Europe

A free Lung Cancer Europe webinar on the gap between progress and reality in small cell lung cancer across Europe. 3 September 2026, 15:00 CEST. Register to join.

041

Lung Cancer Europe @lungcancereurope.bsky.social · 12/08/2026

#LungCancer can develop genetic changes during treatment. ctDNA may help us detect some of those changes through a blood test. A new JAMA review looks at liquid biopsy for treatment selection, response, resistance and recurrence. jamanetwork.com/journals/jam... #LCSM

040

Reposted by Lung Cancer Europe

BTOG @btog.bsky.social · 11/08/2026

Selected key takeaway from our 2026 Annual Conference: - Classification and Management of Peri-Cystic Lesions by Matthew Evison. Full recordings and presentations available to members on our website. #lungcancer #lcsm

021

Reposted by Lung Cancer Europe

OncLive @onclive.bsky.social · 11/08/2026

William J. Phillips, MD, discusses real-world findings on RET inhibitor dose reductions and clinical outcomes in advanced RET fusion-positive NSCLC. #oncology #lcsm #lungcancer

121

Lung Cancer Europe @lungcancereurope.bsky.social · 10/08/2026

Pneumonia accounted for 36% of unplanned hospital admissions in a study of people with NSCLC. Now scientists are working towards a pneumococcal vaccine that could protect against 100+ types of the bacterium. Potentially positive news for #LungCancer. www.nature.com/articles/d41... #LCSM

151

Lung Cancer Europe @lungcancereurope.bsky.social · 08/08/2026

‼️ A tumour isn’t necessarily the same all the way through. Diff populations of cancer cells can exist within it & evolve over time, including under treatment. 🆕 Nature Cancer review explores what this could mean for cancer care. #LungCancer research has been central to this understanding. #LCSM

140